PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, and the use of prognostic tools.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing ...
11h
Exact Imaging Reports Strong Momentum Driven by Commercial Execution and Clinical Validation in 2025
Exact Imaging, a global leader in high-resolution micro-ultrasound systems for prostate cancer, today reported strong ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Updated NCCN Clinical Practice Guidelines in Oncology now recognize that MammaPrint and BluePrint testing can help identify a ...
PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results